NCT05727540

Brief Summary

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 14, 2023

Completed
6 days until next milestone

Study Start

First participant enrolled

February 20, 2023

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

August 23, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

January 11, 2023

Last Update Submit

August 22, 2024

Conditions

Uveitis

Outcome Measures

Primary Outcomes (2)

  • The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    12 months post-treatment

  • The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

    12 months post-treatment

Secondary Outcomes (27)

  • Best corrected visual acuity

    1 month post-treatment

  • Best corrected visual acuity

    3 months post-treatment

  • Best corrected visual acuity

    6 months post-treatment

  • Best corrected visual acuity

    12 months post-treatment

  • Best corrected visual acuity

    24 months post-treatment

  • +22 more secondary outcomes

Study Arms (2)

Noninfectious uveitis

Infectious uveitis

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population are adult uveitis patients.

You may qualify if:

  • The diagnosis is uveitis; The agreement of enrolling this study;

You may not qualify if:

  • Uveitis during the first month after any intraocular surgery; \<18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Central Study Contacts

Ye Dai, doctor

CONTACT

13512721192daiye@gzzoc.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2023

First Posted

February 14, 2023

Study Start

February 20, 2023

Primary Completion

February 20, 2026

Study Completion

March 31, 2026

Last Updated

August 23, 2024

Record last verified: 2024-06

Locations

CN(1)